MARKET

FULC

FULC

Fulcrum Therapeutics
NASDAQ
9.44
-0.02
-0.21%
After Hours: 9.20 -0.24 -2.54% 19:05 03/28 EDT
OPEN
9.48
PREV CLOSE
9.46
HIGH
9.62
LOW
9.24
VOLUME
554.29K
TURNOVER
0
52 WEEK HIGH
13.70
52 WEEK LOW
2.250
MARKET CAP
584.67M
P/E (TTM)
-5.9461
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FULC last week (0318-0322)?
Weekly Report · 3d ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. Granted non-statutory stock options to Patrick Horn, M.D., the company’s newly appointed chief medical officer. The company is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare diseases.
Barchart · 6d ago
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
TipRanks · 03/19 05:50
Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer
Healthcare Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer. Horn's most recently served as the Chief medical officer at HemoShear Therapeutic. The interim Chief Medical officer, Iain Fraser, will remain on the company's executive leadership team.
Seeking Alpha · 03/18 12:02
Weekly Report: what happened at FULC last week (0311-0315)?
Weekly Report · 03/18 11:52
*Fulcrum Therapeutics: Horn Was Chief Medical Officer at Albireo Pharma >FULC
Dow Jones · 03/18 11:01
*Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Dow Jones · 03/18 11:00
Press Release: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D. As Chief Medical Officer. Dr. Horn is a seasoned executive with over 20 years of experience in the field of rare disease drug development. Fulcrum is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Interim chief medical officer, Iain Fraser, will be responsible for leading clinical development.
Dow Jones · 03/18 11:00
More
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Webull offers Fulcrum Therapeutics Inc stock information, including NASDAQ: FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FULC stock methods without spending real money on the virtual paper trading platform.